This research provides data on important demographics and clinical outcome information There is scope to characterize the HER2-low population in the NAC-eligible setting to evaluate whether ADCs focused on this BC subtype may be effective, as they have been shown to improve outcomes in advanced-stage disease. The gene discussed is ERBB2; the disease is breast cancer.